MTOR and schizophrenia: These findings suggest that neonatal treatment with PCP leads to delayed increase in 5-HT6 receptor-mediated mTOR signalling specifically in the PFC, a structure critically implicated in the cognitive deficits relevant to those seen in schizophrenia.